Click any tag below to further narrow down your results
Links
Eli Lilly's CEO, Dave Ricks, discusses the company's strategy to embrace a tech-like model by focusing on GLP-1 drugs, which address obesity and related health issues. This approach positions Lilly differently from traditional pharma, aiming for broader market appeal and higher valuations.